The Biden administration is proposing Medicare and Medicaid coverage for glucagon-like peptide 1 receptor agonist (GLP-1 RA) ...

It’s unclear what impact a change in presidential administration will have on the proposal to widen access for those with obesity.

A new Biden administration proposal could allow millions of Americans with obesity to access weight-loss drugs like Wegovy ...

Share on Facebook Share on Twitter Under a new rule the Biden administration proposed on Tuesday, millions of Americans with ...

Eli Lilly topped the list of the 20 biggest pharmas by market cap with a more than 39% improvement year-to-date in its share ...

Eli Lilly & Co (LLY – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Mohit ...

Pharmaceutical stocks make great additions to any portfolio in any market environment. A good one promises steady revenue ...

Amgen didn't clarify whether the average weight reduction of up to about 20% was a placebo-adjusted figure. It most likely referred to total weight loss, which means the candidate probably isn't any ...

The anti-obesity drug market has expanded significantly in recent years, with the Food and Drug Administration approving a ...

More than seven million additional Americans could get coverage for popular drugs such as Zepbound and Wegovy under the ...